Chapters

Transcript

Video

What are the implications of using anti-TNF biosimilars for clinical practice in RA? For cost savings? What have we learned about biosimilars for infliximab in the setting of RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA